The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Medical Care Facilities
Aier Eye Hospital Group Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.41% CNY13.34
America/New_York / 6 mai 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 123 296 mill |
| EPS: | 0.380 |
| P/E: | 35.11 |
| Earnings Date: | Apr 26, 2024 |
| SharesOutstanding: | 9 242.57 mill |
| Avg Daily Volume: | 77.43 mill |
| RATING 2024-05-06 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.98x |
| Company: PE 35.11 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.39x |
| Company: PE 35.11 | industry: PE 90.65 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY27.84 (108.68%) CNY14.50 |
| Date: 2024-05-06 |
| Expected Trading Range (DAY) |
|---|
|
CNY 13.02 - 13.72 ( +/- 2.62%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY13.34 (3.41% ) |
| Volume | 122.13 mill |
| Avg. Vol. | 77.43 mill |
| % of Avg. Vol | 157.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 300015.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
300015.SZ
Aier Eye Hospital Group Co., Ltd. operates eye care hospitals and institutions. The company offers medical services in the areas of fundus diseases, optometry, refractive correction, glaucoma, corneal diseases, and cataract. It also provides training course for cataract prevention and treatment. The company operates approximately 500 ophthalmic hospitals in mainland China, 86 ophthalmic hospitals in Europe, 1 ophthalmic hospital in the United States, 7 ophthalmic hospitals in Hong Kong, and 12 ophthalmic hospitals in Southeast Asia. The company was founded in 2007 and is headquartered in Changsha, China.